ALV
0.035
52.2%
WLD
0.013
-53.6%
DEV
0.17
47.8%
SPX
0.002
-50%
ROC
0.155
24%
NTM
0.002
-33.3%
PTX
0.058
20.8%
TEM
0.007
-30%
ZAG
0.047
20.5%
CCO
0.003
-25%
CMG
0.12
20%
PGY
0.004
-20%
M4M
0.006
20%
VBS
0.16
-20%
AUZ
0.014
16.7%
DRO
1.97
-19.6%
AX8
0.007
16.7%
KRR
0.013
-18.8%
IMI
0.014
16.7%
EDE
0.043
-17.3%
WJL
0.88
16.6%
AN1
0.005
-16.7%
CRD
0.79
16.2%
AFA
0.049
-15.5%
AGY
0.072
16.1%
ATC
0.022
-15.4%
ATS
0.015
15.4%
AUQ
0.033
-15.4%
STM
0.023
15%
NC1
0.11
-15.4%
GAS
0.032
14.3%
NWM
0.011
-15.4%
TGN
0.16
14.3%
SP8
0.011
-15.4%
TMS
0.008
14.3%
ECS
0.006
-14.3%
MML
0.034
13.3%
HHR
0.006
-14.3%
NOR
0.017
13.3%
IVG
0.03
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759